Failed Pediatric Trial Results Should Be Explicit In Labeling, Cmte. Says
FDA's Pediatric Advisory Committee is asking the agency to explicitly include information from unsuccessful pediatric clinical trials in drug labeling
You may also be interested in...
Future legislation should mandate increased public availability of pediatric trial data, Office of Pediatric Therapeutics Director Dianne Murphy said at a June 13 Institute of Medicine drug forum in Washington, D.C
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.